Original language | English |
---|---|
Pages (from-to) | 801-805 |
Number of pages | 5 |
Journal | Annals of Oncology |
Volume | 32 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2021 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of Oncology, Vol. 32, No. 6, 06.2021, p. 801-805.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
AU - ESMO Guidelines Committee
AU - Vogel, A.
AU - Martinelli, E.
AU - Cervantes, A.
AU - Chau, I.
AU - Daniele, B.
AU - Llovet, J. M.
AU - Meyer, T.
AU - Nault, J. C.
AU - Neumann, U.
AU - Ricke, J.
AU - Sangro, B.
AU - Schirmacher, P.
AU - Verslype, C.
AU - Zech, C. J.
AU - Arnold, D.
N1 - Funding Information: The ESMO Guidelines Committee thank the authors of the full ESMO Clinical Practice Guideline who drafted and reviewed this eUpdate before it was approved by the ESMO Guidelines Committee: A. Vogel, A. Cervantes, I. Chau, B. Daniele, J. M. Llovet, T. Meyer, J.-C. Nault, U. Neumann, J. Ricke, B. Sangro, P. Schirmacher, C. Verslype, C. J. Zech, D. Arnold and E. Martinelli. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. AV reports invited speaker roles for Roche, Sanofi, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, EISAI, IPSEN, INCYTE, Pierre Fabre, Delcath, Lilly and Advisory Boards for Roche, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, EISAI, IPSEN, INCYTE, Pierre Fabre, BTG, Lilly, AstraZeneca and Merck. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, Astra Zeneca, Bayer, Merck-Serono, Pierre Fabre and Sanofi, and grant support from AIRC and speaker support from ESMO. Funding Information: AV reports invited speaker roles for Roche, Sanofi, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, EISAI, IPSEN, INCYTE, Pierre Fabre, Delcath, Lilly and Advisory Boards for Roche, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, EISAI, IPSEN, INCYTE, Pierre Fabre, BTG, Lilly, AstraZeneca and Merck. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, Astra Zeneca, Bayer, Merck-Serono, Pierre Fabre and Sanofi, and grant support from AIRC and speaker support from ESMO.
PY - 2021/6
Y1 - 2021/6
UR - http://www.scopus.com/inward/record.url?scp=85104668795&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2021.02.014
DO - 10.1016/j.annonc.2021.02.014
M3 - Letter
C2 - 33716105
AN - SCOPUS:85104668795
SN - 0923-7534
VL - 32
SP - 801
EP - 805
JO - Annals of Oncology
JF - Annals of Oncology
IS - 6
ER -